Related Experiment Video
Updated: Apr 6, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis
Jérôme Avouac1, Gabriela Riemekasten2, Christophe Meune2
1From the Paris Descartes University, Sorbonne Paris Cité, Rheumatology A Department, Cochin Hospital; Paris Descartes University, Institut National de la Santé Et de la Recherche Médicale, Unité 1016 (INSERM U1016), and Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8104 (CNRS UMR8104), Cochin Institute; Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, Bobigny, France and Unité Mixte de Recherche 942 (UMR 942), Paris, France; Department of Rheumatology, Clinical Immunology, and German Rheumatism Research Centre, a Leibniz institute, Charité-University Medicine, Berlin, Germany.J. Avouac, MD, PhD, Paris Descartes University, Sorbonne Paris Cité, Rheumatology A department, Cochin Hospital, and Paris Descartes University, INSERM U1016, and CNRS UMR8104, Cochin Institute; G. Riemekasten, MD, PhD, Department of Rheumatology, Clinical Immunology, and German Rheumatism Research Centre, a Leibniz institute, Charité-University Medicine; C. Meune, MD, PhD, Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, and UMR 942; B. Ruiz, Assistant Ingenior, Paris Descartes University, INSERM U1016, and CNRS UMR8104, Cochin Institute; A. Kahan, MD, PhD, Paris Descartes University, Sorbonne Paris Cité, Rheumatology A department, Cochin Hospital; Y. Allanore, MD, PhD, Paris Descartes University, Sorbonne Paris Cité, Rheumatology A department, Cochin Hospital, and Paris Descartes University, INSERM U1016, and CNRS UMR8104, Cochin Institute. jerome.avouac@cch.aphp.fr.
Objective:
To determine the predictive value of functional autoantibodies against vascular receptors for the development of ischemic digital ulcers (DU) in patients with systemic sclerosis (SSc).
Methods:
Angiotensin II Type 1 receptor (AT1R) and endothelin 1 Type A receptor (ETAR) autoantibodies were measured at baseline in a prospective cohort of 90 patients with SSc together with 5 validated angiogenic markers. The primary outcome was the occurrence of at least 1 new ischemic DU during the 5-year followup.
Results:
Twenty-four patients developed at least 1 new DU during the followup period. Univariate Cox analysis revealed that concentrations above the median value of anti-AT1R and anti-ETAR antibodies were predictive of the occurrence of ischemic DU (HR 2.85, 95% CI 1.19-6.84 and HR 3.39, 95% CI 1.35-8.50, respectively). A first multivariate Cox analysis including functional autoantibodies and clinical predictors of new DU confirmed anti-ETAR autoantibodies as independent predictors of the occurrence of new ischemic DU (HR 3.15, 95% CI 1.22-8.13) together with a history of DU at baseline. In a second model implemented with angiogenic markers, anti-ETAR autoantibodies remained an independent predictor of the occurrence of new ischemic DU (HR 9.59, 95% CI 1.75-52.64) together with the presence at baseline of active DU or history of DU.
Conclusion:
Anti-ETAR autoantibodies can be used together with the presence of current or past DU to identify patients with SSc who are at risk for the development of subsequent DU. These autoantibodies may allow for earlier management and therapeutic intervention.
More Related Videos
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
10:05Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
Published on: January 17, 2018
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease I: Introduction
Coronary Artery Disease I: Introduction